Share on twitter
Share on LinkedIn
Share on Facebook
Email to a friend
Print page
This statement provides guidance on contraceptive options for women with prolactinoma
This document is up-to-date
Updated Document - Please note, this document was updated in September 2016.
This document is up-to-date
This statement aims to encourage the consistent and safe management of women requesting intrauterine contraception (IUC) and subdermal implants (SDI) who are taking anticoagulants or antiplatelet medications. It is primarily aimed at clinicians working in primary care and community sexual and reproductive health clinics.
Please read this guidance document in conjunction with any relevant clinical statements for this topic.
This statement provides guidance on contraceptive options for women taking (or whose male partners are taking) known teratogenic drugs or drugs with potential teratogenic effects. Download the full document and save.
This document is up-to-date
Sexually active women of reproductive age with eating disorders require effective contraception despite the fact that amenorrhoea and anovulation are common in this population. This statement provides clinicians with a resource for best helping women with eating disorders choose the most appropriate and acceptable contraception for them. Download and save the document here.
This document is up-to-date
This statement provides guidance on contraceptive choices for transgender and non-binary people and their partners, who are engaging in vaginal sex where there is a risk of pregnancy. The statement also offers general sexual health advice for these groups.
This document is up-to-date
